Characteristics of adults who wish to enter a trial of growth hormone replacement.

2.50
Hdl Handle:
http://hdl.handle.net/10541/98815
Title:
Characteristics of adults who wish to enter a trial of growth hormone replacement.
Authors:
Holmes, Sarah J; Shalet, Stephen M
Abstract:
OBJECTIVE: It is possible that the degree of perceived well-being may influence the decision of an adult with GH deficiency to receive GH replacement. We have therefore sought factors which influenced whether or not such a patient wished to enter a study of GH replacement. DESIGN: Biochemical, anthropometric and demographic characteristics, and well-being, of patients who chose to enter a 12-month study of GH replacement at Christie Hospital NHS Trust were compared with those of patients who declined to enter the study. PATIENTS: Sixty-five adults with GH deficiency who entered a study of GH replacement and 33 adults with GH deficiency who were approached but who declined to enter the study. MEASUREMENTS: The two groups of patients were compared according to sex, age, height, weight, body mass index, peak serum GH response to provocative testing, estimated duration of GH deficiency, whether GH deficiency was of childhood or adult onset, presence or absence of additional pituitary hormone deficiencies, aetiology of GH deficiency, previous therapeutic interventions, employment status, marital status and living arrangement (65 entered vs 33 declined to enter). Well-being or distress was measured using the Nottingham Health Profile (NHP) (65 entered vs 20 declined to enter) and the Psychological General Well-being Schedule (PGWBS) (33 entered vs 19 declined to enter). RESULTS: Those who entered the study had significantly higher scores on the energy (P = 0.03) and emotional reaction (P = 0.02) subsections and on the total score (P = 0.04) of the NHP, indicating greater distress, and had a significantly lower score (P = 0.009) on the vitality subsection of the PGWBS, again indicating greater distress. Those who entered the study had a significantly lower prevalence of non-functioning pituitary adenoma (P = 0.02) but there was no other difference in biochemical, anthropometric or demographic characteristics between the two groups. CONCLUSION: Adults who enter a study of GH replacement exhibit greater distress on questionnaire assessment than those who decline to enter such a study. This bias must be considered when interpreting studies of the effect of GH replacement on well-being in adults.
Affiliation:
Department of Endocrinology, Christie Hospital NHS Trust, Manchester, UK.
Citation:
Characteristics of adults who wish to enter a trial of growth hormone replacement. 1995, 42 (6):613-8 Clin. Endocrinol
Journal:
Clinical Endocrinology
Issue Date:
Jun-1995
URI:
http://hdl.handle.net/10541/98815
DOI:
10.1111/j.1365-2265.1995.tb02688.x
PubMed ID:
7634502
Type:
Article
Language:
en
ISSN:
0300-0664
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHolmes, Sarah Jen
dc.contributor.authorShalet, Stephen Men
dc.date.accessioned2010-05-14T09:42:49Z-
dc.date.available2010-05-14T09:42:49Z-
dc.date.issued1995-06-
dc.identifier.citationCharacteristics of adults who wish to enter a trial of growth hormone replacement. 1995, 42 (6):613-8 Clin. Endocrinolen
dc.identifier.issn0300-0664-
dc.identifier.pmid7634502-
dc.identifier.doi10.1111/j.1365-2265.1995.tb02688.x-
dc.identifier.urihttp://hdl.handle.net/10541/98815-
dc.description.abstractOBJECTIVE: It is possible that the degree of perceived well-being may influence the decision of an adult with GH deficiency to receive GH replacement. We have therefore sought factors which influenced whether or not such a patient wished to enter a study of GH replacement. DESIGN: Biochemical, anthropometric and demographic characteristics, and well-being, of patients who chose to enter a 12-month study of GH replacement at Christie Hospital NHS Trust were compared with those of patients who declined to enter the study. PATIENTS: Sixty-five adults with GH deficiency who entered a study of GH replacement and 33 adults with GH deficiency who were approached but who declined to enter the study. MEASUREMENTS: The two groups of patients were compared according to sex, age, height, weight, body mass index, peak serum GH response to provocative testing, estimated duration of GH deficiency, whether GH deficiency was of childhood or adult onset, presence or absence of additional pituitary hormone deficiencies, aetiology of GH deficiency, previous therapeutic interventions, employment status, marital status and living arrangement (65 entered vs 33 declined to enter). Well-being or distress was measured using the Nottingham Health Profile (NHP) (65 entered vs 20 declined to enter) and the Psychological General Well-being Schedule (PGWBS) (33 entered vs 19 declined to enter). RESULTS: Those who entered the study had significantly higher scores on the energy (P = 0.03) and emotional reaction (P = 0.02) subsections and on the total score (P = 0.04) of the NHP, indicating greater distress, and had a significantly lower score (P = 0.009) on the vitality subsection of the PGWBS, again indicating greater distress. Those who entered the study had a significantly lower prevalence of non-functioning pituitary adenoma (P = 0.02) but there was no other difference in biochemical, anthropometric or demographic characteristics between the two groups. CONCLUSION: Adults who enter a study of GH replacement exhibit greater distress on questionnaire assessment than those who decline to enter such a study. This bias must be considered when interpreting studies of the effect of GH replacement on well-being in adults.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshEmotions-
dc.subject.meshFemale-
dc.subject.meshGrowth Hormone-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPatient Acceptance of Health Care-
dc.subject.meshQuality of Life-
dc.subject.meshSocioeconomic Factors-
dc.titleCharacteristics of adults who wish to enter a trial of growth hormone replacement.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalClinical Endocrinologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.